SCHEMBL3322286

SCHEMBL3322286

Cc1ccc(COCC(=O)C23CC4CC(CC(C4)C2)C3)cn1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 3/20 0.70
HSP90AA1 P07900 2/20 0.47
ALDH1A1 P00352 5/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
CYP17A1 P05093 3/20 0.46
CYP19A1 P11511 3/20 0.46
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
KDM4E B2RXH2 3/20 0.42
TP53 P04637 1/20 0.42
ATM Q13315 1/20 0.42
GAA P10253 1/20 0.42
MAPT P10636 1/20 0.42
THRB P10828 1/20 0.42
HPGD P15428 1/20 0.42
ALOX15 P16050 1/20 0.42
ALOX12 P18054 1/20 0.42
HTT P42858 1/20 0.42
HSD17B10 Q99714 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1769934 0.83 HSD11B1 (0.61) HSD11B1HSP90AA1ALDH1A1SMN1; SMN2CYP17A1
SCHEMBL3323197 0.82 HSD11B1 (0.72) HSD11B1HSP90AA1ALDH1A1SMN1; SMN2CYP17A1
SCHEMBL3321259 0.82 HSD11B1 (1.00) HSD11B1HSP90AA1ALDH1A1SMN1; SMN2CYP17A1
SCHEMBL13333256 0.80 HSD11B1 (0.50) HSD11B1HSP90AA1ALDH1A1SMN1; SMN2MEN1
SCHEMBL3326655 0.79 HSD11B1 (0.67) HSD11B1HSP90AA1ALDH1A1MEN1KMT2A
SCHEMBL3320789 0.79 HSD11B1 (0.67) HSD11B1HSP90AA1ALDH1A1SMN1; SMN2CYP17A1
SCHEMBL13688856 0.78 HSD11B1 (0.55) HSD11B1HSP90AA1ALDH1A1SMN1; SMN2CYP17A1
SCHEMBL3322521 0.77 HSD11B1 (0.72) HSD11B1HSP90AA1ALDH1A1MEN1KMT2A
SCHEMBL3321257 0.76 HSD11B1 (0.64) HSD11B1HSP90AA1ALDH1A1SMN1; SMN2CYP17A1
SCHEMBL13333552 0.76 HSD11B1 (0.71) HSD11B1HSP90AA1ALDH1A1SMN1; SMN2CYP17A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100120789-A1 Compound STERIX LIMITED (GB) 2010-05-13 US disclosed
US-20090042929-A1 11-Beta-Hydroxysteroid Dehydrogenase Inhibitors STERIX LIMITED (GB) 2009-02-12 US disclosed
EP-1861384-A1 11-BETA-HYDROXYSTEROID DEHYDROGENASE INHIBITORS Sterix Limited (GB) 2007-12-05 EP disclosed
WO-2006100502-A1 11-BETA-HYDROXYSTEROID DEHYDROGENASE INHIBITORS STERIX LIMITED (GB) 2006-09-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042929-A1 11-Beta-Hydroxysteroid Dehydrogenase Inhibitors HSD3B1, HSD3B2, HSD11B1 HSD11B1 3/4885HSP90AA1 4402/4885ALDH1A1 437/4885
US-20100120789-A1 Compound NR0B2, NR0B1, NR4A1 HSD11B1 73/4885HSP90AA1 4874/4885ALDH1A1 3143/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.